Diagnosis and management of pancreatic cancer

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 14, 2013, Pages 1219-1226

  Kanji, Zaheer S ^a,b   Gallinger, Steven ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ERLOTINIB; ERYTHROMYCIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; METOCLOPRAMIDE; OXALIPLATIN; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ALCOHOL CONSUMPTION; ALLERGY; ANASTOMOSIS LEAKAGE; ANOREXIA; BACKACHE; BLOOD GROUP O; BONE MARROW SUPPRESSION; CANCER SCREENING; CANCER SURVIVAL; CELL ADHESION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DECOMPRESSION; DELAYED GASTRIC EMPTYING; DERMATITIS; DIAGNOSTIC ACCURACY; DIARRHEA; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ENZYME REPLACEMENT; EPIGASTRIC PAIN; FAMILIAL CANCER; FAMILY HISTORY; FATIGUE; HIGH RISK PATIENT; HUMAN; INTERSTITIAL LUNG DISEASE; JAUNDICE; LIVER TOXICITY; NASOGASTRIC DECOMPRESSION; NAUSEA; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL SUPPORT; PANCREAS CANCER; PANCREAS CELL; PANCREAS DUCT; PANCREAS INSUFFICIENCY; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PATIENT CARE; POSTOPERATIVE COMPLICATION; RASH; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SMOKING; STEATORRHEA; STOMACH EMPTYING; STOMATITIS; SURGICAL MORTALITY; THROMBOEMBOLISM; VOMITING; WEIGHT REDUCTION;

EID: 84886378527     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121368     Document Type: Review

References (62)

1. Al-Sukhni W, Borgida A, Rothenmund H et al. Screening for pancreatic cancer in a high risk cohort: an eight year experience. J GastroIntestinal Surg 2012;16:771-83.
2. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2012. Toronto (ON): Canadian Cancer Society; 2012.
3. Woodmass J, Lipschitz J, McKay A. Physician attitudes and treatment of patterns for pancreatic cancer. World J Surg Oncol 2011;9:21.
4. Hidalgo M. Pancreas cancer. NEJM 2010;362:1605-17.
5. Pancreatic cancer survival by stage. Atlanta (GA): American Cancer Society; 2013. Available: www .cancer .org/cancer/pancreaticcancer/ detailedguide/pancreatic-cancer-survival-rates (accessed 2013 Mar. 21).
6. Samuel N, Hudson TJ. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol 2012;9:77-87.
7. Klein AP. Identifying people at high risk of developing pancreatic cancer. Nat Rev Cancer 2013;13:66-74.
8. Wolpin BM, Kraft P, Gross M, et al. Genotype derived ABO blood groups alleles and the risk of pancreatic cancer: data from the Pancreatic Cancer Consortium. Cancer Res 2010;70:1015-23.
9. Anderson LN, Cotterchio M, Gallinger S. Lifestyle, dietary and medical history factors associated with pancreas cancer risk in Ontario, Canada. Cancer Causes Control 2009;20:825-34.
10. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med 2009;133:365-74.
11. Hahn SA, Greenhalf B, Ellis I, et al. BRCA 2 mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003;95:214-21. (Pubitemid 36240634)
12. Jones S, Hruban RH, Kamiyama M, et al. Exome sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009;324:217.
13. Slater EP, Langer P, Niemczyk E, et al. Prevalence of BRCA2 and CDKN2A mutations in German familial pancreatic cancer families. Fam Cancer 2010;9:335-43.
14. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7.
15. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006;4:766-81. (Pubitemid 43825802)
16. Brentnall TA. Pancreatic cancer surveillance: learning as we go. Am J Gastroenterol 2011;106:955-6.
17. Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology 2010;139:1076-80.
18. Artinyan A, Soriano PA, Prendergast C, et al. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB 2008;10:371-6.
19. Porta M, Fabregat X, Malats N, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumor site and stage. Clin Transl Oncol 2005;7:189-97.
20. Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10:88-95.
21. Miura F, Takada T, Amano H, et al. Diagnosis of pancreatic cancer. HPB 2006;8:337-42. (Pubitemid 44473457)
22. Birchard KR, Semelka RC, Hyslop WB, et al. Suspected pancreatic cancer: evaluation by dynamic gadolinium-enhanced 3D gradient-echo MRI. AJR Am J Roentgenol 2005;185:700-3.
23. Wight CO, Zaitoun AM, Boulton-Jones JR, et al. Improving diagnostic yield of biliary brushings cytology for pancreatic cancer and cholangiocarcinoma. Cytopathology 2004;15:87-92. (Pubitemid 38482594)
24. van der Gaag NA, Rauws EA, van Eijck CH et al. Preoperative biliary drainage for cancer of the head of the pancreas. NEJM 2010;362:129-37.
25. Ruckert F, Pilarsky C, Grutzmann R. Serum tumor markers in pancreatic cancer - recent discoveries. Cancers 2010;2:1107-24.
26. Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2012: Featured updates to the NCCN guidelines. J Natl Compr Can Netw 2012;10:703-13.
27. Barugola G, Partelli S, Crippa S, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg 2012;203:132-9.
28. Neoptolemos JP, Stocken DB, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10. (Pubitemid 38339364)
29. Neuhaus P, Riess H, Post S et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resectable pancreatic cancer. J Clin Oncol 2008 (May 20 suppl) [abstract].
30. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine base chemotherapy before and after fluorouracil based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299: 1019-26. (Pubitemid 351347058)
31. Neoptolemos JP, Stocken DB, Tudur Smith C, et al. Adjuvant 5- fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009;100:246-50.
32. Múller SA, Hartel M, Mehrab A, et al. Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg 2009;13:784-92.
33. Sultana A, Smith CT, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007;25:2607-15. (Pubitemid 47041235)
34. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326-31. (Pubitemid 350003022)
35. Loehrer PJ, Powell ME, Cardenes HR et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008 (26 suppl) [abstract].
36. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
37. Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82.
38. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-25.
39. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 Randomized Trial. J Clin Oncol 2013;31:23-9.
40. Venkat R, Edit BH, Schulick RD, et al. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: A systematic review and meta-analysis. Ann Surg 2012;255:1048-59.
41. Ho CK, Kleeff J, Friess H, et al. Complications of pancreatic surgery. HPB (Oxford) 2005;7:99-108. (Pubitemid 40767044)
42. Reddy S, Wolfgang CL, Cameron JL, et al. Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long term survival. Ann Surg 2009;250:282-7.
43. Malleo G, Crippa S, Buttirini G, et al. Delayed gastric emptying after pylorus - preserving pancreaticoduodenectomy: validation of international study group of pancreatic surgery classification and analysis of risk factors. HPB 2010;12:610-8.
44. van Berge Henegouwen MI, De Wit LT, Van Gulik TM, et al. Incidence, risk factors, and treatment of pancreatic leakage after pancreaticoduodenectomy: drainage versus resection of the pancreatic remnant. J Am Coll Surg 1997;185:18-24. (Pubitemid 27276737)
45. Ausania F, Cook N, Jamieson N, et al. Impact of pancreatic leaks on survival following pancreaticoduodenectomy. JOP 2010;11:226-9.
46. Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004;198:722-31. (Pubitemid 38542900)
47. Keim V, Klar E, Poll M, et al. Postoperative care following pancreatic surgery: surveillance and treatment. Dtsch Arztebl Int 2009; 106:789-94.
48. Duffy MJ, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010;21:441-7.
49. Boeck S, Ankerst DP, Heinemann V. The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta- analysis. Oncology 2007;72:314-21. (Pubitemid 351238143)
50. Neoptolemos JP, Stocken DB, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-81.
51. Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/ neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267.
52. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7: 163-72.
53. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern cooperative oncology group trial E2297. J Clin Oncol 2002; 20: 3270-5. (Pubitemid 34831525)
54. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-52. (Pubitemid 46630743)
55. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23: 3509-16.
56. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-7. (Pubitemid 46954645)
57. Xie DR, Liang HL, Wang Y et al. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based chemotherapy therapy and gemcitabine alone. World J Gastroenterol 2006;12: 6973-81. (Pubitemid 44834888)
58. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 2007;25:1960-6. (Pubitemid 46972777)
59. Petersen GM, de Andrade M, Goggins M, et al. Pancreatic Cancer Genetic Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2006;15:704-10.
60. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012;2:41-6.
61. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal abberations in axon guidance pathways. Nature 2012;491:399-405.
62. Hudson TJ, Anderson W, Artez A, et al. International network of cancer genome projects. Nature 2010;464:993-8.